• NICE nod for GSK’s ‘bubble baby syndrome’ gene therapy pharmatimes
    October 24, 2017
    The National Institute for Health and Care Excellence has published draft guidance recommending GlaxoSmithKline’s gene therapy Strimvelis as an option for treating an ultra-rare immune deficiency condition commonly referred to as bubble baby syndrome.
PharmaSources Customer Service